NEW YORK (
CHANGE IN RATINGS
was downgraded to hold at TheStreet Ratings.
was initiated with a buy rating at MKM Partners. $34 price target. Company is a market leader and could achieve $6 earnings power by 2020, MKM said.
(ASH - Get Report)
was downgraded at Jefferies to hold from buy. $97 price target. Multiple headwinds and investor thesis in asset reshuffling may not play out, Jefferies said.
(DPZ - Get Report)
was downgraded at Oppenheimer to perform from outperform. Valuation call, as the stock has nearly tripled over the past two years, Oppenheimer said.
(FB - Get Report)
was downgraded at Pivotal Research to hold from buy. Valuation call, based on a $48 price target, Pivotal said.
was upgraded at Sterne Agee to buy. $56 price target. Estimates were also increased, as the company can grow in multiple operating environments, Sterne Agee said.
was upgraded to buy at TheStreet Ratings.
(MUR - Get Report)
was initiated with a neutral rating at at Credit Suisse. Valuation call, based on a $70 price target, Credit Suisse said.
was initiated with a buy rating at Bank of America/Merrill Lynch. $46 price target. Company can continue to grow by focusing on rare diseases, BofA/Merrill said.
Stock Comments / EPS Changes
Bank of New York Mellon
numbers were cut at Jefferies. Shares are now seen reaching $34. Estimates were also lowered as activity is down despite higher equity markets, Jefferies said. Hold rating.
numbers were boosted at Credit Suisse. Shares are now seen reaching $36. Company is seeing stronger volumes, Credit Suisse said. Underperform rating.
was cut from the Conviction Buy List at Goldman Sachs. Estimates were also cut, given the company's new guidance, Goldman said. $118 price target.
numbers were raised at Credit Suisse. Shares are now seen reaching $287. Estimates were also increased, as the company remains leveraged to the aerospace cycle, Credit Suisse said. Outperform rating.
numbers were cut at Jefferies. Shares are now seen reaching $31. Estimates were also lowered as latest data suggests it is underperforming RCL, Jefferies said. Hold rating.
numbers were cut at Jefferies. Shares are now seen reaching $100. Estimates were also lowered on unfavorable channel work, Jefferies said. Buy rating.
>To submit a news tip, email:
and become a fan on